Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ESMO Open
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Clinical Trial Goss - BioCanRx
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - European Urology
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial - The Lancet Oncology
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial - Lung Cancer
Multicenter Clinical Trial is Currently Recruiting MCC Patients - Merkel Cell Carcinoma
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study -
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Annals of Oncology
![PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/63896bbe64c237acb7d4260c2e84ab3aa4969933/38-Figure3-1.png "PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar")
PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar
New Protocol for Advanced Kidney Cancer Involving Drug Combo of Avelumab and Axitinib - Thailand Medical News
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice - Cancer Treatment Reviews
Hutson Compares Avelumab for PD-L1 Positive Versus PD-L1 Negative Bladder Cancer
2018-1357
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial - Journal of Thoracic Oncology
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Avelumab Maintenance Therapy Shows Favorable Results After Frontline Chemotherapy in Bladder Cancer
Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma - Kazandjian - 2021 - The Oncologist - Wiley Online Library
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial - The Lancet Oncology
Select clinical trials evaluating avelumab in combination with other... | Download Table
Anti-PD-L1 antibodies atezolizumab, avelumab and durvalumab currently... | Download Scientific Diagram
